Literature DB >> 1397889

Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics.

P J Pockros1, K T Esrason, C Nguyen, J Duque, S Woods.   

Abstract

Serial ascites and plasma volumes were measured during diuresis in nine patients with ascites caused by peritoneal carcinomatosis, four patients with chylous malignant ascites, and three patients with portal hypertension-related ascites caused by massive hepatic metastases. Oral diuretics were given to achieve an adequate natriuresis on a sodium-restricted diet. During the study period (7.8 +/- 3.2 days), patients with peritoneal carcinomatosis and chylous ascites lost 0.49 +/- 0.31 and 0.51 +/- 0.42 kg/day in weight, respectively, with negligible change in ascites volumes (-0.03 +/- 0.11 and 0.02 +/- 0.09 L/day). Patients with ascites caused by massive hepatic metastasis lost 1.06 +/- 0.15 kg/day in weight (P = 0.01 for massive hepatic metastasis vs. peritoneal carcinomatosis) and 0.23 +/- 0.13 L/day of ascites (P less than 0.05 vs. other groups). Plasma volume changes were not significantly different among the three groups. Patients with edema (9/16) had a greater natriuresis and daily weight loss. Three patients with peritoneal carcinomatosis and one with chylous ascites developed renal dysfunction or symptomatic hypotension. No patient with massive hepatic metastasis developed these complications. In patients with ascites caused by peritoneal carcinomatosis or chylous malignant ascites there is no mobilization of ascites, whereas in patients with massive hepatic metastasis, ascites may be mobilized with diuretics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397889     DOI: 10.1016/0016-5085(92)91520-e

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

1.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

2.  Respiratory distress due to malignant ascites palliated by hyperthermic intraperitoneal chemotherapy.

Authors:  Marijn Marinus Leonardus van den Houten; Thijs Ralf van Oudheusden; Michael Derek Philip Luyer; Simon Willem Nienhuijs; Ignace Hubertus Johannes Theodorus de Hingh
Journal:  World J Gastrointest Surg       Date:  2015-03-27

Review 3.  Malignant ascites: pathophysiology and treatment.

Authors:  Emanuel Cavazzoni; Walter Bugiantella; Luigina Graziosi; Maria Silvia Franceschini; Annibale Donini
Journal:  Int J Clin Oncol       Date:  2012-03-31       Impact factor: 3.402

Review 4.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

5.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

6.  Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Authors:  Christopher M Moore; David H Van Thiel
Journal:  World J Hepatol       Date:  2013-05-27

Review 7.  Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Authors:  Filippo Bellati; Chiara Napoletano; Ilary Ruscito; Maria Pastore; Milena Pernice; Morena Antonilli; Marianna Nuti; Pierluigi Benedetti Panici
Journal:  Invest New Drugs       Date:  2009-11-24       Impact factor: 3.850

Review 8.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 9.  Treatment of malignant ascites.

Authors:  Michael Chung; Peter Kozuch
Journal:  Curr Treat Options Oncol       Date:  2008-09-06

Review 10.  Symptom Management in Pancreatic Cancer.

Authors:  Kristina G Lee; Varun Roy; Meghan Laszlo; Katelyn M Atkins; Katrina J Lin; Shant Tomassian; Andrew E Hendifar
Journal:  Curr Treat Options Oncol       Date:  2021-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.